Sweden · Delayed Price · Currency is SEK OssDsign AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a 3.6% USD revenue decline and a 17.1% SEK drop, mainly due to currency effects and operational slowdowns. Leadership changes, sales force expansion, and new product launches are expected to drive improved momentum in H2 2026.
Fiscal Year 2025
-
Q4 saw 24% constant currency growth and a 96.3% gross margin, with full year sales up 45% to SEK 180.2 million. Strategic focus is on U.S. expansion, new product launches, and achieving SEK 400 million sales by 2028.
-
The company is focused on property investment, with a strong European presence and a strategy to grow recurring revenues through co-investments and scalable products. Recent restructuring aims to clarify earnings and strengthen core markets, while maintaining a solid cash position.
-
Strong organic growth and record EBIT were achieved despite seasonality and currency headwinds, with robust gross margins and continued expansion in the US market. Execution of the new growth strategy is underway, supported by a strengthened balance sheet and upcoming product launches.
-
Organic growth reached 73% year-over-year, with gross margin at 96.8% and LTM revenue up 68%. Over SEK 160 million was raised to fund the Scale to Profit strategy, targeting SEK 400 million in sales by 2028 and major U.S. market expansion.
-
A real-world registry study of 108 complex spinal fusion patients achieved an 88.4% fusion rate at 12 months, with high success across all high-risk groups and significant improvements in pain and quality of life. These results exceed expectations and support broader clinical adoption.
-
A new strategy aims to accelerate growth in the U.S. spine biologics market, targeting sales above SEK 400 million and profitability by 2028. Plans include doubling the sales force, launching two new products, expanding into adjacent segments, and building robust clinical evidence, all fully funded by a recent share issue.
-
Strong sales and margin growth were reported, with OssDsign Catalyst surpassing 10,000 U.S. patients and robust clinical evidence supporting rapid bone fusion. Market access is at 10% with significant expansion potential, and new products are in development to address evolving surgical needs.
-
Q1 2025 saw 65% revenue growth and a 96.4% gross margin, with strong U.S. market momentum and expanding clinical evidence. Cash position is solid, and the company is focused on U.S. growth and upcoming real-world registry data publication.
Fiscal Year 2024
-
Achieved over 100% year-over-year revenue growth and a gross margin above 95% in 2024, with strong U.S. market expansion and improved cash flow. Over 90% of the spinal orthobiologics market remains untapped, supporting a positive outlook.
-
A strategic shift to orthobiologics has driven record growth, high margins, and strong operating leverage. The differentiated product is gaining rapid adoption, with expansion into new clinical segments and a focus on untapped U.S. market potential.
-
Q3 2024 saw 114% sales growth and a record 96.9% gross margin, driven by U.S. market expansion and production efficiency. Gross margin guidance was raised to above 93%, with continued strong growth expected as the company targets the large untapped U.S. market.
-
Q2 2024 saw 143% sales growth year-over-year and gross margin rise to 93.2%. Major milestones included surpassing SEK 100 million in rolling sales and securing key U.S. contracts, with significant untapped market potential remaining.